Poly(ethylene glycol)-modified proteins: Implications for poly(lactide-co-glycolide)-based microsphere delivery

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 88-98

  Pai, Sheetal S ^a   Tilton, Robert D ^a   Przybycien, Todd M ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Microencapsulation; PEGylation; Protein delivery; Proteinde naturation; Sustained release

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOPEPTIN; ARESTIN; ASPARAGINASE MACROGOL; BROMOCRIPTINE MESILATE; BUSERELIN ACETATE; CHYMOTRYPSIN A; CYCLOSPORIN A; HUMAN GROWTH HORMONE; LEUPRORELIN; LYSOZYME; MACROGOL; MICROSPHERE; MINOCYCLINE; OCTREOTIDE; PAMORELIN; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLYGLACTIN; POLYGLYCOLIDE; POLYLACTIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBONUCLEASE A; RISPERIDONE; SOMATOSTATIN DERIVATIVE; TETANUS TOXOID; THYROTROPIN; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACROMEGALY; CARCINOID SYNDROME; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; ENDOMETRIOSIS; HUMAN; HYPOPHYSIS TUMOR; MICROENCAPSULATION; NONHUMAN; PERIODONTAL DISEASE; PROSTATE CANCER; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION;

ADSORPTION; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; GELS; HALF-LIFE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MICROSPHERES; MURAMIDASE; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; PROTEIN STABILITY; PROTEINS; SILICON DIOXIDE; SOLVENTS;

EID: 65549096370     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9081-8     Document Type: Review

References (67)

1. J. M. Harris, and R. B. Chess. Effect of PEGylation on pharmaceuticals. Nat. Rev. 2:214-221 (2003).
2. P. Hutton, G. Cooper, F. M. James, F. M. James III, and J. F. Butterworth IV. Anaesthesia: Fundamental principles and practice, Informa Health Care, London, 2002.
3. Genentech, http://www.gene.com/gene/products/information/opportunistic/ nutropin-aq/insert.jsp. Accessed various dates.
4. FDA, http://www.fda.gov/MEDWATCH/SAFETY/2004/oct_PI/Nutropin_PI.pdf. Accessed various dates.
5. Pfizer, http://www.pfizer.com/files/products/uspi_somavert.pdf. Accessed various dates.
6. T. Tice. Delivering with depot formulations. Drug Deliv. Technol. 4: 44-47 (2004).
7. D. L. Wise, D. J. Trantolo, R. T. Marino, and J. P. Kitchell. Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial agents and vaccines. Adv. Drug Deliv. Rev. 1(3):269-269 (1988).
8. S. Cohen, T. Yoshioka, M. Lucarelli, L. H. Hwang, and R. Langer. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8:713-720 (1991).
9. D. T. O'Hagan, M. Singh, and R. K. Gupta. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev. 32:225-246 (1998).
10. FDA, http://vm.cfsan.fda.gov/%7Edms/eafus.html. Accessed various dates.
11. K. L. Smith, M. E. Schimpf, and K. E. Thompson. Bioerodible polymers for delivery of macromolecules. Adv. Drug Deliv. Rev. 4:343-357 (1990).
12. J. Cleland. Protein delivery from biodegradable microspheres. In L. M. Sanders, and R. W. Henderen (eds.), Protein Delivery: Physical Systems, Plenum, New York, 1997, pp. 1-43.
13. M. A. Tracy, K. L. Ward, L. Firouzabadian, Y. Wang, N. Dong, R. Qian, and Y. Zhang. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 20:1057-1062 (1999).
14. M. Ahlheim, M. Ausborn, D. Bodmer, C. Schoch. Ophthalmic depot formulations for periocular or subconjunctival administration. European patent EP1429725.
15. M. Diwan, and T. G. Park. Stabilization of recombinant interferon-a by PEGylation for encapsulation in PLGA microspheres. Int. J. Pharm. 252:111-122 (2003).
16. S. M. Daly, T. M. Przybycien, and R. D. Tilton. Adsorption of poly(ethylene glycol)-modified ribonuclease A to a poly(lactide-co-glycolide) surface. Biotechnol. Bioeng. 90(7):856-868 (2005).
17. M. Van de Weert, W. E. Hennink, and W. Jiskoot. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17:1159-1167 (2000).
18. O. L. Johnson, W. Jaworowicz, J. L. Cleland, L. Bailey, M. Charnis, E. Duenas, C. Wu, D. Shepard, S. Magil, T. Last, A. J. S. Jones, and S. D. Putney. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14:730-735 (1997).
19. M. A. Tracy. Development and scale-up of a microsphere protein delivery system. Biotechnol. Prog. 14:108-115 (1998).
20. Alkermes, http://www.alkermes.com/newsroom/showArticle.aspx?id=278. Access Aug 13, 2007.
21. I. J. Castellanos, W. Al-Azzam, and K. Griebenow. Effect of the covalent modification with poly(ethylene glycol) on α-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres. J. Pharm. Sci. 94(2):327-340 (2005).
22. A. Sanchez, J. L. Vila-Jato, and M. J Alonso. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporine A. Int. J. Pharm. 99:263-273 (1993).
23. M. Diwan, and T. G. Park. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Release. 73:233-244 (2001).
24. C. Pérez, P.D. Jesús, and K. Griebenow. Preservation of lysozyme structure and function upon encapsulation and release from poly(lactic-co-glycolic) acid microspheres prepared by the water-in-oil-in-water method. Int. J. Pharm. 248:193-206 (2002).
25. D. Bodmer, T. Kissel, and E. Traechslin. Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. J. Control. Release. 21:129-138 (1992).
26. M. J. Alonso, S. Cohen, T. G. Park, R. K. Gupta, G. R. Siber, and R. Langer. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm. Res. 10:945-953 (1993).
27. T. Heya, H. Okada, Y. Ogawa, and H. Toguchi. In vitro and in vivo evaluation of thyrotropin releasing hormone release from copoly(dl-lactic/glycolic acid) microspheres. Int. J. Pharm. 72:199-205 (1991).
28. G. Crotts, H. Sah, and T. G. Park. Adsorption determines in vitro protein release rate from biodegradable microspheres: Quantitative analysis of surface area during degradation. J. Control. Release. 47:101-111 (1997).
29. J. L. Cleland, M. F. Powell, and S. J. Shire. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carr. Syst. 10:307-377 (1993).
30. J. M. Harris, N. E. Martin, and M. Modi. Pegylation: A novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:539 (2001).
31. M. Michaelis, J. Cinati, J. Cinati, P. Pouckova, K. Langer, J. Kreuler, and J. Matousek. Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice. Anticancer Drugs. 13:149-154 (2002).
32. R. B. Greenwald, Y. H. Choe, J. McGuire, and C. D. Conover. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:217-250 (2003).
33. J. Y. Shu, C. Tan, W. D. DeGrado, and T. Xu. New design of helix bundle peptide-polymer conjugates. Biomacromolecules. 9:2111-2117 (2008).
34. Y. Noguchi, J. Wun, R. Duncan, J. Strohalm, K. Ulbrish, T. Akaike, and H. Maeda. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89:307-314 (1998).
35. Y. Murakami, Y. Tabata, and Y. Ikada. Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection. Drug Delivery. 4:23-32 (1997).
36. A.S. Morar, J. L. Schrimsher, and M. D. Chavez. PEGylation of proteins: a structural approach: Structural properties of PEGylated proteins could play an increasingly important role in developing optimal therapeutic protein drugs. (Protein PEGylation). Biopharm International. 19(4):34 (2006).
37. C. Perez, I. J. Castellanos, H. R. Costantino, W. Al-Azzam, and K. Griebenow. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J. Pharm. Pharmacol. 54(3):310-313 (2001).
38. J. L. Cleland, and A. J. S. Jones. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res. 13:1464-1475 (1996).
39. M. J. Alonso, R. K. Gupta, C. Min, G. R Siber, and R. Langer. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine. 12:299-306 (1994).
40. H. Sah. Protein instability toward organic solvent/water emulsification: Implications for protein microencapsulation into microspheres. PDA J. Pharm. Sci. Technol. 53:3-10 (1999).
41. H. K. Kim, and T. G. Park. Microencapsulation of human growth hormone within biodegradable polyester microspheres: Protein aggregation stability and incomplete release mechanism. Biotechnol. Bioeng. 65:659-667 (1999).
42. G. Crotts, and T. G. Park. Preparation of porous and nonporous biodegradable polymeric hollow microspheres. J. Control. Release. 35:91-105 (1995).
43. T. Knubovets, J. J. Osterhout, and A. M. Klibanov. Structure of lysozyme dissolved in neat organic solvents as assessed by NMR and CD spectroscopies. Biotechnol. Bioeng. 63:242-248 (1999).
44. R. Jain, N. H. Shah, A. W. Malick, and C. T. Rhodes. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches. Drug Devel. Ind. Pharm. 24(8):703-727 (1998).
45. R. Arshady. Preparation of biodegradable microspheres and microcapsules: 2. Polylactides and related polyesters. J. Control. Release. 17:1-21 (1999).
46. J.-M. Péan, M.-C. Venier-Julienne, F. Boury, P. Menei, B. Denizot, and J.-P. Benoit. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control. Release. 56:175-187 (1998).
47. J. Rojas, H. Pinto-Alphandary, E. Leo, S. Pecquet, P. Couvreur, and E. Fattal. Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly(D,L-lactide-co-glycolide) microspheres. Int. J. Pharm. 183:67-71 (1999).
48. H. Sah. Stabilization of proteins against methylene chloride/water interface induced denaturation and aggregation. J. Control. Release. 58:143-151 (1999).
49. K.S. Suslick, D. A. Hammerton, and R. E. Cline. The sono-chemical hot spot. J. Am. Chem. Soc. 108:5641-5642 (1986).
50. P. Reisz, and T. Kondo. Free radical formation induced by ultrasound and its biological implications. Free Radic. Biol. Med. 13:247-270 (1992).
51. M. F. Zambaux, F. Bonneaux, R. Gref, E. Dellacherie, and C. Vigneron. Preparation and characterization of protein C-loaded PLA nanoparticles. J. Control. Release. 60:179-188 (1999).
52. M. Morlock, H. Koll, G. Winter, and T. Kissel. Microencapsulation of rh-erythropoietin using biodegradable poly(D,L-lactide-co-glycolide): Protein stability and the effect of stabilizing excipients. Eur. J. Pharm. Biopharm. 43:29-36 (1997).
53. T. Uchida, K. Shiosaki, Y. Nakada, K. Fukada, Y. Eda, S. Tokiyoshi, N. Nagareya, and K. Matsuyama. Microencapsulation of hepatitis B core antigen for vaccine preparation. Pharm. Res. 15:1708-1713 (1998).
54. H. Sah. Protein behavior at the water/methylene chloride interface. J. Pharm. Sci. 88:1320-1325 (1999).
55. C. Perez, and K. Griebenow. Improved activity and stability of lysozyme at the water/CH2Cl2 interface: Enzyme unfolding and aggregation and its prevention by polyols. J. Pharm. Sci. 53:1217-1226 (2001).
56. E. S. Lee, K. H. Park, D. M. Kim, I. S. Park, H. Y. Min, D. H. Lee, S. Kim, J. H. Kim, and K. Na. Protein complexed with chondroitin sulfate in poly(lactide-co-glycolide) microspheres. Biomaterials. 28(17):2754-2762 (2007).
57. B. Bittner, C. Witt, K. Mader, and T. Kissel. Degradation and protein release properties of microspheres prepared from biodegradable poly(lactide-co-glycolide) and ABA triblock copolymers: Influence of buffer media on polymer erosion and bovine serum albumin release. J. Control. Release. 60:297-309 (1999).
58. T. G. Park, H. Y. Lee, and Y. S. Nam. A new preparation method for protein loaded poly (D,L-lactic-co-glycolic acid) microspheres and protein release mechanism study. J. Control. Release. 55:181-191 (1998).
59. G. Crotts, and T. G. Park. Stability and release of bovine serum albumin encapsulated within poly(D,L-lactide-co-glycolide) microparticles. J. Control. Release. 44:123-134 (1997).
60. S. M. Butler, M. A. Tracy, and R. D. Tilton. Adsorption of serum albumin to thin films of poly(lactide-co-glycolide). J. Control. Release. 58:335-347 (1999).
61. P. Bouillot, N. Ubrich, F. Sommer, T. M. Duc, J. P. Loeffler, and E. Dellacherie. Protein encapsulation in biodegradable amphiphilic microspheres. Int. J. Pharm. 181:159-172 (1999).
62. A. Klibanov and R. S. Langer. Methods of decreasing the hydrophobicity of fibroblast and other interferons. United States Patent 4,414,147.
63. K. D. Hinds, K. M. Campbell, K. M. Holland, D. H. Lewis, C. A. Piche, and P. G. Schmidt. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J. Control. Release. 104:447-460 (2005).
64. O. B. Kinstler, N. E. Gabriel, C. E. Farrar, R. B. DePrince. N-Terminally chemically modified protein compositions and methods. United States Patent 5, 824, 784.
65. S. M. Daly, T. M. Przybycien, and R. D. Tilton. Adsorption of poly(ethylene glycol)-modified lysozyme to silica. Langmuir. 21:1328-1337 (2005).
66. S. M. Daly, T. M. Przybycien, and R. D. Tilton. Coverage dependent orientation of lysozyme adsorbed on silica. Langmuir. 19:3848-3857 (2003).
67. S. M. Daly, T. M. Przybycien, and R. D. Tilton. Aggregation of lysozyme and poly(ethylene glycol)-modified lysozyme after adsorption to silica. Colloids Surf., B Biointerfaces. 57(1):81-88 (2007).